China Biotech Deal Volume Surged 81% as Western Pharma Doubles Down
A BIO China panel based on anonymous survey data from BD heads and senior dealmakers revealed that nearly 80%...
business development
Chinese Biotechs Shift From Building to Partnering as Deal Values Double
At BIO China, pharma executives and investors debated whether Chinese biotechs should pursue full integration or adopt partnership-led growth...
China Biotech Dealmaking Shifts from Opportunistic to Strategic
At BIO-Europe Spring 2026, industry leaders from AstraZeneca, Kelun-Biotech, Harbour BioMed, and Panacea Capital dissected the structural forces driving...
AI Rewires Biopharma BD — From Data Grunt to Strategic Lever
At BIO-Europe Spring 2026, a cross-sector panel dissected how generative AI is restructuring the business development workflow — from...
The $29 Billion March Wasn’t a Spike — It’s the Opening Bid for a Restructured Industry
Seven biopharma deals worth $29 billion closed in the final two weeks of March 2026. The street called it...